AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1194144 — intervention group
Group type: COMPARATOR
Intervention: No inspiratory elastic load (control)
Number of subjects: 7
Study 31363878 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA with iodixanol (270 mg I/mL), scanned with 100 kV, reconstruction by AIDR
Number of subjects: 68
Study 31363878 — intervention group
Group type: COMPARATOR
Intervention: CCTA with iopromide (370 mg I/mL), scanned with 120 kV, reconstruction by filtered back projection
Number of subjects: 68
Study 28524027 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy (CPT)
Number of subjects: 68
Study 25374039 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-bias-habit-changing intervention (2.5-hour workshop)
Number of subjects: 92
Study 24101053 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab plus erlotinib in MET-positive patients (n = 66)
Number of subjects: 137
Study 24101053 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab plus erlotinib in MET-negative patients (n = 62)
Number of subjects: 137
Study 24101053 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo plus erlotinib) in MET-positive patients (n = 62)
Number of subjects: 137
Study 24101053 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab plus erlotinib
Number of subjects: 137
Study 21938606 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Botox®)
Number of subjects: 0
Study 21938606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19285163 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontrast head computed tomography (CT) scan
Number of subjects: 0
Study 19285163 — intervention group
Group type: EXPERIMENTAL
Intervention: Head magnetic resonance imaging (MRI)
Number of subjects: 0
Study 19285163 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain specific serum biomarkers
Number of subjects: 0
Study 19285163 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontrast head CT scan with normal neurologic evaluation
Number of subjects: 0
Study 16956484 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional emergency surgery
Number of subjects: 0
Study 16956484 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment
Number of subjects: 0
Study 16956484 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 0
Study 16956484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 0
Study 15228830 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogue (Sandostatin 300 microgram subcutaneously/day in three divided doses)
Number of subjects: 33
Study 15228830 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods (nil per orum, total parenteral nutrition, antibiotics, skin and wound care, control of sepsis)
Number of subjects: 33
Study 15228830 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogue
Number of subjects: 33
Study 11097669 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 1 mg morphine
Number of subjects: 39
Study 11097669 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine with 50 microg fentanyl
Number of subjects: 39
Study 11097669 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine with 10 microg sufentanil
Number of subjects: 39
Study 11097669 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine alone
Number of subjects: 39
Study 9411596 — intervention group
Group type: EXPERIMENTAL
Intervention: Babyhaler with a face mask
Number of subjects: 100
Study 9411596 — intervention group
Group type: EXPERIMENTAL
Intervention: Aeroscopic
Number of subjects: 100
Study 9411596 — intervention group
Group type: EXPERIMENTAL
Intervention: Other spacer devices (Aerochamber, Nebuhaler, Volumatic)
Number of subjects: 100
Study 8477148 — intervention group
Group type: EXPERIMENTAL
Intervention: l-alpha-glyceryl-phosphorylcholine (alpha GPC)
Number of subjects: 126
Study 8477148 — intervention group
Group type: COMPARATOR
Intervention: ST200 (acetyl-l-carnitine)
Number of subjects: 126
Study 2948256 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (2.5-7.5 mg, administered gradually by mouth)
Number of subjects: 17
Study 2948256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 2948256 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 micrograms by dosimetric aerosol)
Number of subjects: 17
Study 2948256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (40 micrograms by dosimetric aerosol)
Number of subjects: 17
Study 30322633 — intervention group
Group type: EXPERIMENTAL
Intervention: In-cabin intubation protocol
Number of subjects: 14
Study 30322633 — intervention group
Group type: COMPARATOR
Intervention: Standard outdoor intubation
Number of subjects: 14
Study 27524393 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill training plus VR
Number of subjects: 302
Study 27524393 — intervention group
Group type: COMPARATOR
Intervention: Treadmill training alone
Number of subjects: 302
Study 27524393 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups after training
Number of subjects: 302
Study 25977176 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self-examination (BSE) and breast physical examination (BPx)
Number of subjects: 12660
Study 25977176 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12660
Study 23458938 — intervention group
Group type: EXPERIMENTAL
Intervention: No. 14 pediatric Foley catheter/balloon for 5 days (n=13)
Number of subjects: 28
Study 23458938 — intervention group
Group type: COMPARATOR
Intervention: No balloon (n=15)
Number of subjects: 28
Study 20377770 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Number of subjects: 108
Study 20377770 — intervention group
Group type: COMPARATOR
Intervention: Fe chloride
Number of subjects: 108
Study 18197911 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP levels in pleural fluid for CHF patients
Number of subjects: 40
Study 18197911 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP level >or=2220 pg/mL
Number of subjects: 40
Study 17163250 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20mg
Number of subjects: 635
Study 17163250 — intervention group
Group type: COMPARATOR
Intervention: Candesartan cilexetil 8mg
Number of subjects: 635
Study 14583239 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training program (8 weeks)
Number of subjects: 28
Study 14583239 — intervention group
Group type: COMPARATOR
Intervention: Wait-control group
Number of subjects: 28
Study 10072664 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone addition to neuroleptic treatment
Number of subjects: 10
Study 10072664 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapramine addition to neuroleptic treatment
Number of subjects: 10
Study 7488404 — intervention group
Group type: EXPERIMENTAL
Intervention: Halsted mastectomy
Number of subjects: 1973
Study 7488404 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrantectomy plus radiotherapy
Number of subjects: 1973
Study 7488404 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumpectomy plus radiotherapy
Number of subjects: 1973
Study 7488404 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrantectomy without radiotherapy
Number of subjects: 1973
Study 7488404 — intervention group
Group type: COMPARATOR
Intervention: Halsted mastectomy, Quadrantectomy plus radiotherapy, Lumpectomy plus radiotherapy, Quadrantectomy without radiotherapy
Number of subjects: 1973
Study 1790543 — intervention group
Group type: EXPERIMENTAL
Intervention: Topilene (generic formulation) cream
Number of subjects: 0
Study 1790543 — intervention group
Group type: COMPARATOR
Intervention: Diprolene (innovator formulation) cream
Number of subjects: 0
Study 1790543 — intervention group
Group type: EXPERIMENTAL
Intervention: Topilene (generic formulation) ointment
Number of subjects: 0
Study 1790543 — intervention group
Group type: COMPARATOR
Intervention: Diprolene (innovator formulation) ointment
Number of subjects: 0
Study 6264507 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.243% sodium fluoride-silica abrasive dentifrice
Number of subjects: 1824
Study 6264507 — intervention group
Group type: COMPARATOR
Intervention: 0.4% stannous fluoride-calcium pyrophosphate abrasive dentifrice
Number of subjects: 1824
Study 31475494 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS at Zusanli (ST36) and Sanyinjiao (SP6) starting 30 min before surgery to the end of surgery
Number of subjects: 40
Study 31475494 — intervention group
Group type: COMPARATOR
Intervention: Control group received TEAS at the same acupoints with minimum current intensity
Number of subjects: 40
Study 28495411 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied intraorally and extraorally with a 660-nm and 810-nm laser, respectively, at 200 mW for 10 seconds, 2 J, 1.5 J/cm2 and 7 J/cm2, repeated 2 times per week for 3 weeks.
Number of subjects: 16
Study 28495411 — intervention group
Group type: COMPARATOR
Intervention: Control side received laser simulation instead of actual laser therapy.
Number of subjects: 16
Study 26159384 — intervention group
Group type: COMPARATOR
Intervention: 35% hydrogen peroxide (single session‐45 min)
Number of subjects: 140
Study 26159384 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate dentifrice and in‐office experimental pastes (D4 and D5)
Number of subjects: 140
Study 26159384 — intervention group
Group type: EXPERIMENTAL
Intervention: D1‐experimental dentifrice containing bioactive glass‐ceramic
Number of subjects: 140
Study 26159384 — intervention group
Group type: EXPERIMENTAL
Intervention: D4-experimental bioactive glass‐ceramic and D5-experimental Bioglass type 45S5
Number of subjects: 140
Study 23377193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 73
Study 23377193 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (TZD) use
Number of subjects: 73
Study 23377193 — intervention group
Group type: EXPERIMENTAL
Intervention: A1C levels
Number of subjects: 73
Study 21748445 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin administration (group A)
Number of subjects: 60
Study 21748445 — intervention group
Group type: COMPARATOR
Intervention: No melatonin administration (group B)
Number of subjects: 60
Study 19487639 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly incontinence
Number of subjects: 2994
Study 19487639 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic whites
Number of subjects: 2994
Study 19487639 — intervention group
Group type: EXPERIMENTAL
Intervention: African Americans
Number of subjects: 2994
Study 19487639 — intervention group
Group type: EXPERIMENTAL
Intervention: Asians
Number of subjects: 2994
Study 19487639 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI > or = 35 kg/m(2)
Number of subjects: 2994
Study 19487639 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior hysterectomy
Number of subjects: 2994
Study 19487639 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary tract infection in the prior year
Number of subjects: 2994
Study 16231342 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Exposure (ME) therapy
Number of subjects: 45
Study 16231342 — intervention group
Group type: COMPARATOR
Intervention: Nondirective (ND) therapy
Number of subjects: 45
Study 15317832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast
Number of subjects: 0
Study 15317832 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 0
Study 15317832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast in smokers
Number of subjects: 0
Study 15317832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilomilast in nonsmokers
Number of subjects: 0
Study 12152675 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, 20 mg/day
Number of subjects: 59
Study 12152675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 9828991 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Living Programme (DLP)
Number of subjects: 0
Study 9828991 — intervention group
Group type: EXPERIMENTAL
Intervention: DLP for 20 months followed by standard care
Number of subjects: 0
Study 9828991 — intervention group
Group type: COMPARATOR
Intervention: Standard care throughout
Number of subjects: 0
Study 7714303 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (400 mg/day)
Number of subjects: 109
Study 7714303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (75 mg/day)
Number of subjects: 109
Study 7714303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 7714303 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 109
Study 2649118 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 0.05 mg/kg/day
Number of subjects: 20
Study 2649118 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 0.025 mg/kg/day
Number of subjects: 20
Study 2649118 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (high dose)
Number of subjects: 20
Study 2649118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 412041 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside-Sodium (NPN)
Number of subjects: 12
Study 412041 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Nitroglycerin (NTG)
Number of subjects: 12
Study 6274503 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia alone
Number of subjects: 43
Study 6274503 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia combined with high-dose-rate external beam radiotherapy
Number of subjects: 43
Study 6274503 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial thermoradiography
Number of subjects: 43
Study 6274503 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 43
Study 6274503 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 43
Study 6274503 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 43
Study 30045133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral (CB) intervention
Number of subjects: 40
Study 30045133 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 29334416 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use (units per week)
Number of subjects: 0
Study 29334416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarettes smoked per day
Number of subjects: 0
Study 29334416 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking initiation
Number of subjects: 0
Study 27029707 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored high-dose oral vitamin D supplementation (T)
Number of subjects: 215
Study 27029707 — intervention group
Group type: COMPARATOR
Intervention: Conventional vitamin D and calcium supplementation (C)
Number of subjects: 215
Study 27029707 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored high-dose oral vitamin D supplementation (T) after switching from C
Number of subjects: 215
Study 25212095 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg caffeine/kg body mass)
Number of subjects: 90
Study 25212095 — intervention group
Group type: COMPARATOR
Intervention: Placebo energy drink (0 mg caffeine/kg body mass)
Number of subjects: 90
Study 22370839 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus casei and Bifidobacterium breve), administered three times a day for an average treatment duration of 5.06±2.18 days
Number of subjects: 70
Study 22370839 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered three times a day for an average treatment duration of 5.49±3.17 days
Number of subjects: 70
Study 21164556 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AEx)
Number of subjects: 19
Study 21164556 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (REx)
Number of subjects: 19
Study 21164556 — intervention group
Group type: COMPARATOR
Intervention: Sedentary Control
Number of subjects: 19
Study 18269776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 600 mg/m2 and epirubicin 75 mg/m2
Number of subjects: 56
Study 18269776 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 400‐600 mg/m2 and epirubicin 60‐90 mg/m2
Number of subjects: 56
Study 16430107 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Perindopril
Number of subjects: 19257
Study 12091596 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly subcutaneous epoetin beta treatment
Number of subjects: 173
Study 12091596 — intervention group
Group type: COMPARATOR
Intervention: Three times weekly subcutaneous epoetin beta treatment
Number of subjects: 173
Study 10191298 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-heparin lipoprotein lipase (PH-LPL) activity in CAD patients
Number of subjects: 730
Study 10191298 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of PH-LPL activity in CAD patients
Number of subjects: 730
Study 10191298 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of PH-LPL activity in CAD patients
Number of subjects: 730
Study 10191298 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PH-LPL activity in CAD patients
Number of subjects: 730
Study 7789550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nal-Glu 100 micrograms/kg per day + T enanthate 50 mg IM weekly
Number of subjects: 30
Study 7789550 — intervention group
Group type: EXPERIMENTAL
Intervention: Nal-Glu 200 micrograms/kg per day + T enanthate 50 mg IM weekly
Number of subjects: 30
Study 7789550 — intervention group
Group type: COMPARATOR
Intervention: Placebo + T enanthate 50 mg IM weekly
Number of subjects: 30
Study 2112069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (FF, 120 mg/day for 7 days)
Number of subjects: 20
Study 2112069 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal-weight women)
Number of subjects: 20
Study 2112069 — intervention group
Group type: COMPARATOR
Intervention: Basal conditions (before any drug administration)
Number of subjects: 20
Study 435347 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive anaesthesia using halothane
Number of subjects: 30
Study 435347 — intervention group
Group type: COMPARATOR
Intervention: Normotensive control group
Number of subjects: 30
Study 30383246 — intervention group
Group type: EXPERIMENTAL
Intervention: RV‐A16 inoculum (n = 26)
Number of subjects: 36
Study 30383246 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 36
Study 29040589 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa followed by 300 IU highly purified HMG (hp-HMG)
Number of subjects: 152
Study 29040589 — intervention group
Group type: COMPARATOR
Intervention: 300 IU daily recombinant FSH (rFSH)
Number of subjects: 152
Study 25646321 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WG) consumption for 4-8 weeks
Number of subjects: 80
Study 25646321 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WG) consumption for 8 weeks
Number of subjects: 80
Study 25646321 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain wheat (WG) consumption
Number of subjects: 80
Study 25646321 — intervention group
Group type: COMPARATOR
Intervention: Refined wheat (RW) consumption
Number of subjects: 80
Study 23337405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary shunt
Number of subjects: 40
Study 23337405 — intervention group
Group type: COMPARATOR
Intervention: Snare
Number of subjects: 40
Study 21880032 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 489
Study 21880032 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 489
Study 19523725 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread enriched with black currant press residue
Number of subjects: 36
Study 19523725 — intervention group
Group type: COMPARATOR
Intervention: Control bread without press residue
Number of subjects: 36
Study 17378195 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with hyperbaric oxygenation
Number of subjects: 72
Study 17378195 — intervention group
Group type: COMPARATOR
Intervention: Routine medicine and hyperbaric oxygenation
Number of subjects: 72
Study 14975455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus drug-eluting stent
Number of subjects: 100
Study 14975455 — intervention group
Group type: COMPARATOR
Intervention: Conventional stents
Number of subjects: 100
Study 11323087 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg alpha-lipoic acid per day
Number of subjects: 84
Study 11323087 — intervention group
Group type: COMPARATOR
Intervention: No antioxidant treatment (Control)
Number of subjects: 84
Study 9578794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 110
Study 9578794 — intervention group
Group type: COMPARATOR
Intervention: Scintigraphy
Number of subjects: 110
Study 7901636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (2.4 mg retinol) and placebo iron tablets
Number of subjects: 251
Study 7901636 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (60 mg elemental iron) and placebo vitamin A
Number of subjects: 251
Study 7901636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (2.4 mg retinol) and iron (60 mg elemental iron)
Number of subjects: 251
Study 7901636 — intervention group
Group type: COMPARATOR
Intervention: Both placebos
Number of subjects: 251
Study 2832202 — intervention group
Group type: EXPERIMENTAL
Intervention: MACC polychemotherapy (methotrexate, doxorubicin HCl, cyclophosphamide and lomustine)
Number of subjects: 8
Study 2832202 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (before treatment)
Number of subjects: 8
Study 31124428 — intervention group
Group type: EXPERIMENTAL
Intervention: CDI prevention collaborative intervention including onsite infection control and antimicrobial stewardship assessments, interactive learning sessions, and communication improvement initiative during June 2015‐June 2016.
Number of subjects: 52
Study 31124428 — intervention group
Group type: EXPERIMENTAL
Intervention: CDI prevention collaborative intervention
Number of subjects: 52
Study 31124428 — intervention group
Group type: COMPARATOR
Intervention: Control group of 27 ACHs in 3 San Francisco Bay Area counties
Number of subjects: 52
Study 27813716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied on the right side (diode laser 660 nm, 40 mW, 1 min, 2.4 J of total energy)
Number of subjects: 10